Soren Acquisition Corp.
SORN
NASDAQ Global Market9.96
USD
- -
- -
CIK
0002086263
ISIN
KYG8274J1031
CUSIP
G8274J103
Return %
Stock
S&P500
1Y
0.81
15.98
3Y
0.81
62.25
5Y
0.81
67.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Arghavan Di Rezze
- Full Time Employees
- 2
- Sector
- Financial Services
- Industry
- Financial - Conglomerates
- Address
- 1000 Brickell Avenue Miami FL United States of America 33131
- IPO Date
- Feb 27, 2026
- CIK
- 0002086263
- Website
- sorenacquisition.com
- Similar Companies
- Business
- Soren Acquisition Corp. Class A Ordinary Shares operates as a blank-check company formed to effect one or more potential business combinations with healthcare-related entities. It focuses on identifying, pursuing, and consummating mergers, capital stock exchanges, asset acquisitions, stock purchases, reorganizations, or similar transactions. The company intends to target healthcare, life sciences, and related sectors through a qualifying business combination. Industry and business segments: SPAC/blank-check vehicle; healthcare and life sciences transaction focus; potential cross-border deal activity. Target markets: healthcare providers, biopharma, medical technology, healthcare services, and related healthcare ecosystem players seeking strategic growth or consolidation opportunities. Geographic operations: headquartered in Miami, Florida, with the potential for transactions that may involve U.S. and international target companies; contemplated geographic flexibility in pursuit of a suitable healthcare-focused partner. Founding year and headquarters: founded in 2025; headquarters located in Miami, Florida. Recent major changes and movements: completes and documents its initial public offering activities and related private placements; maintains a defined deadline to complete a qualifying business combination (late 2020s timeline referencing 2028 redemption option if no transaction is closed); engages in strategic disclosures and governance updates as part of ongoing SPAC activity; continues to pursue partnerships, acquisitions, or strategic alignments within healthcare, subject to regulatory and market conditions. Subsidiaries or parent relationships: operates as a standalone SPAC with no disclosed material subsidiaries at inception; any sponsor affiliations and related-party transactions are disclosed in regulatory filings as part of standard SPAC governance.